A comparison of intra-arterial and intravenous tissue-type plasminogen activator on autologous arterial emboli in the cerebral circulation of rabbits.
- 1 March 1994
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 25 (3) , 651-655
- https://doi.org/10.1161/01.str.25.3.651
Abstract
The efficacy of thrombolytic therapy for treatment of embolic stroke has been a subject of both experimental and clinical examination. The aim of this study was to compare the efficacy, in regard to reduction of volume of ischemic brain, of two different modes of administration (ie, intra-arterial and intravenous) of tissue-type plasminogen activator (TPA) given 30 minutes after experimental embolic stroke in rabbits. A randomized, blinded, controlled experimental trial was undertaken. Embolic stroke was simulated in rabbits by injecting fragments of autologous arterial thrombus into one internal carotid artery. Thirty minutes after embolization, the rabbits were blindly treated with 2 mg/kg intra-arterial TPA, 2 mg/kg intravenous TPA, or saline (all n = 10). Six hours after embolization the rabbits were killed. The brains were perfused with triphenyltetrazolium chloride and cut into 0.5-cm-thick coronal sections, and the areas of ischemia were measured. Administration of TPA resulted in a significant reduction in the volume of ischemic cerebral injury (P < .0001): control animals sustained ischemic injury to 20.1 +/- 4.6% (mean +/- SD) of total brain compared with 4.6 +/- 4.1% for animals treated with intra-arterial TPA and 3.4 +/- 2.6% for those treated with intravenous TPA. The difference between intra-arterial and intravenous TPA treatment was not significant (P = .786). In this rabbit model of embolic stroke, administration of TPA within 30 minutes resulted in a dramatic reduction in the amount of ischemic injury, with equal efficacy for the two modes of administration. These results favor the treatment of acute embolic stroke with intravenous TPA, given the rapidity with which intravenous therapy can be established in the clinical setting.Keywords
This publication has 23 references indexed in Scilit:
- Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarctionJournal of the American College of Cardiology, 1992
- Thrombolytic therapy in cerebrovascular disordersProgress in Cardiovascular Diseases, 1992
- Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activatorJournal of the American College of Cardiology, 1989
- Selective decrease in lysis of old thrombi after rapid administration of tissue-type plasminogen activatorJournal of the American College of Cardiology, 1989
- RANDOMISED DOUBLE-BLIND TRIAL OF RECOMBINANT PRO-UROKINASE AGAINST STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1989
- Evaluation of Recombinant Tissue Plasminogen Activator in Embolic StrokeNeurosurgery, 1989
- Digital angiographic quantification of blood flow dynamics in embolic stroke treated with tissue-type plasminogen activatorJournal of Neurosurgery, 1987
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985
- Functional recovery of cortical neurons as related to degree and duration of ischemiaAnnals of Neurology, 1983
- Thrombolysis with Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis. EFFECT OF MOLECULAR FORM AND DOSE OF ACTIVATOR, AGE OF THE THROMBUS, AND ROUTE OF ADMINISTRATIONJournal of Clinical Investigation, 1983